Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › chemotherapy

chemotherapy

30 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of chemotherapy

49 trials tracked of chemotherapy: 18 in phase 3 or 4 and 8 with published results. The most-cited published study has 645 citations.

49Trials tracked
18Phase 3 & 4
0Recruiting
8With published results
Phase distribution
Phase 4 1 Phase 3 17 Phase 2 21 Phase 1 2 Other / NA 8
  1. Phase 3 S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Completed · 645 cited
  2. Phase 3 Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) Completed · 358 cited
  3. Phase 3 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Completed · 143 cited
  4. Phase 3 Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma Completed · 101 cited
  5. Phase 3 Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma Completed · 40 cited
  6. Phase 3 Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel Completed · 26 cited
Show 43 more trials
  1. Phase 3 AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed · 21 cited
  2. Phase 3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Completed · 13 cited
  3. Phase 4 Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population Completed
  4. Phase 3 A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) Completed
  5. Phase 3 Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy Completed
  6. Phase 3 THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. Completed
  7. Phase 3 A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer. Completed
  8. Phase 3 A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients Completed
  9. Phase 3 A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA) Completed
  10. Phase 3 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Completed
  11. Phase 3 Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer Completed
  12. Phase 3 A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations Completed
  13. Phase 2 Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Completed
  14. Phase 2 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Completed
  15. Phase 2 Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects Completed
  16. Phase 2 Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients Completed
  17. Phase 2 The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts Completed
  18. Phase 2 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed
  19. Phase 2 Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma Completed
  20. Phase 2 Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed
  21. Phase 2 Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer Completed
  22. Phase 2 Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC) Completed
  23. Phase 2 Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia Completed
  24. Phase 2 Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) Completed
  25. Phase 2 A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE) Completed
  26. Phase 2 Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection Completed
  27. Phase 2 Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study Completed
  28. Phase 2 Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg Completed
  29. Phase 2 Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer Completed
  30. Phase 2 NOLAN: Naproxen or Loratadine and Neulasta Completed
  31. Phase 2 A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) Completed
  32. Phase 2 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer Completed
  33. Phase 2 CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer Completed
  34. Phase 1 A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT Completed
  35. Phase 1 A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas Completed
  36. N/A Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses Completed
  37. N/A Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide Completed
  38. N/A Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay Completed
  39. N/A Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer Completed
  40. N/A Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer Completed
  41. N/A Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Completed
  42. N/A A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma Completed
  43. N/A An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer Completed

Showing the 49 most-cited and recently-updated of 49 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
Oncology Meta-analysis
Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer Chemoimmunotherapy Shows Higher Response Rates in Bladder Cancer
This network meta-analysis of 2234 patients with muscle-invasive bladder cancer compares neoadjuvant chemoimmunotherapy (NICT), chemotherapy…
A new analysis shows that combining chemotherapy and immunotherapy may lead to higher response rates for patients with muscle-invasive bladd…
Frontiers Jun 13, 2026
Angiogenesis inhibitors combined with chemotherapy improve progression-free survival in advanced breast cancer patients
Oncology Meta-analysis
Angiogenesis inhibitors combined with chemotherapy improve progression-free survival in advanced breast cancer patients Adding angiogenesis inhibitors to chemotherapy helps advanced breast cancer patients stay disease-free longer
This systematic review and meta-analysis of phase II and III trials evaluated angiogenesis inhibitors combined with chemotherapy versus chem…
A large review of eight thousand four hundred patients found that adding angiogenesis inhibitors to standard chemotherapy improved how long …
Frontiers Jun 5, 2026
Systemic cancer treatment linked to 5% skeletal muscle loss over 90 days
Oncology Meta-analysis
Systemic cancer treatment linked to 5% skeletal muscle loss over 90 days Cancer treatment linked to muscle loss in large analysis
A systematic review and meta-analysis of 78 studies (n=10,502) found that systemic cancer treatment is associated with a small but significa…
Chemotherapy and immunotherapy may cause muscle loss in cancer patients, a new analysis of 78 studies finds.
Jun 3, 2026
PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer
Allergy & Immunology Meta-analysis
PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer Immunotherapy combo extends life in advanced endometrial cancer
A meta-analysis of 4,052 patients from RCTs found that adding PD-1/PD-L1 inhibitors to chemotherapy improved overall survival (median 43.7 v…
Adding immunotherapy to chemo boosted survival by over 14 months in advanced endometrial cancer, a new analysis finds.
Frontiers Jun 2, 2026
Chemoimmunotherapy improves survival in solid tumors regardless of liver metastasis status
Gastroenterology Meta-analysis
Chemoimmunotherapy improves survival in solid tumors regardless of liver metastasis status Chemoimmunotherapy helps solid tumor patients, with or without liver metastases
This systematic review and meta-analysis evaluated 25915 patients with solid tumors receiving chemoimmunotherapy versus chemotherapy alone. …
For people with solid tumors, adding immunotherapy to chemo helps survival whether or not cancer has spread to the liver.
Jun 1, 2026
Immune checkpoint inhibitors before lung cancer surgery show acceptable safety profile
Pulmonology & Critical Care Meta-analysis
Immune checkpoint inhibitors before lung cancer surgery show acceptable safety profile Immunotherapy before lung cancer surgery is safe, study finds
This meta-analysis of patients with resectable non-small cell lung cancer found that neoadjuvant or perioperative immune checkpoint inhibito…
A new analysis of 2,691 patients shows that immunotherapy before lung cancer surgery is feasible, but comes with specific surgical challenge…
Jun 1, 2026
Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
Pulmonology & Critical Care Meta-analysis
Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer Skin reactions in lung cancer patients may signal longer life with certain treatments
This meta-analysis evaluated patients with non-small cell lung cancer receiving anti-PD-1, PD-L1, or chemotherapy. The analysis found that c…
A large review found that specific skin reactions linked to cancer drugs are connected to longer survival times for some lung cancer patient…
Jun 1, 2026
Case report review highlights suspicion of breast cancer metastasis to thyroid in a 54-year-old woman
Orthopedics & Sports Medicine Sys. Review
Case report review highlights suspicion of breast cancer metastasis to thyroid in a 54-year-old woman Breast cancer can spread to the thyroid gland in rare cases
This case report review describes a 54-year-old woman with a history of breast cancer who developed metastasis to the thyroid. The authors n…
A single case report shows a 54-year-old woman survived after breast cancer spread to her thyroid, highlighting the need for careful diagnos…
Frontiers May 25, 2026
Network meta-analysis suggests immune checkpoint inhibitor regimens improve survival in advanced gastric cancer compared to chemotherapy alone
Oncology Meta-analysis
Network meta-analysis suggests immune checkpoint inhibitor regimens improve survival in advanced gastric cancer compared to chemotherapy alone New analysis suggests dual-target immune checkpoint inhibitors may improve survival for advanced gastric cancer patients
This network meta-analysis evaluated immune checkpoint inhibitor regimens versus chemotherapy for patients with advanced gastric cancer. The…
A large network meta-analysis suggests dual-target immune checkpoint inhibitors combined with chemotherapy may improve survival for advanced…
May 24, 2026
PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer
Oncology Meta-analysis
PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer New meta-analysis shows PD-1 inhibitors improve response rates for dMMR colorectal cancer
This meta-analysis of 1460 patients with dMMR/MSI-H metastatic colorectal cancer found that PD-1/PD-L1 monotherapy significantly improved ob…
A large review of 1460 patients found PD-1 inhibitors significantly improved tumor response rates compared to chemotherapy for dMMR colorect…
May 22, 2026
Meta-analysis links emotional distress to worse outcomes in advanced lung cancer
Oncology Meta-analysis
Meta-analysis links emotional distress to worse outcomes in advanced lung cancer Emotional distress linked to worse lung cancer survival
This systematic review and meta-analysis of 911 patients with advanced NSCLC found emotional distress was significantly associated with redu…
For people with advanced lung cancer, feeling emotionally distressed is tied to lower survival and worse treatment response, a new analysis …
Frontiers May 21, 2026
Network meta-analysis compares therapies for liver metastatic uveal melanoma
Oncology Meta-analysis
Network meta-analysis compares therapies for liver metastatic uveal melanoma Liver-directed therapy combined with ICIs leads for metastatic uveal melanoma survival
This systematic review and network meta-analysis synthesized evidence on therapeutic modalities for patients with liver metastatic uveal mel…
A network meta-analysis of 2,585 patients found liver-directed therapy combined with immune checkpoint inhibitors offered the best survival …
Frontiers May 20, 2026

All chemotherapy Articles